EX1 0.57% 87.5¢ exopharm limited

Ann: December 2018 Quarterly Activities Report, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,452 Posts.
    lightbulb Created with Sketch. 314
    Things that caught my eye in EX1 first ANN:

    ”The Company anticiapates results from the initial non-clinical animal study to be released in Feb 2019”.

    ”Overall, this work supports the plan to release the first clinical Plexaris drug product to a study site. Managing Exomeres to to a first in human small scale clinical study of Autologous Plexaris product for wound healing.  This is currently planned for commencement CY 2019”. Around mid year I believe & we will have some results this month, pre-clinical.  This is going to be great if trials successful.  GLTAH

 
watchlist Created with Sketch. Add EX1 (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.